CDA inactivates 5AC, a potent anticancer agent that is widely used in the treatment of MDS, and treatment with 5AC induces the enhanced expression of the CDA gene in MDS cells, which is accompanied by the altered methylation of the CpG sites at its 5′-flanking region. This evidence concerns the gene CDA and myelodysplastic syndrome.